Angiotensin 1-7 is primarily involved in the regulation of the cardiovascular system through its vasodilatory, anti-fibrotic, and anti-inflammatory effects. It acts mainly via the Mas receptor, counterbalancing the actions of angiotensin II, which promotes vasoconstriction and hypertension. This peptide plays a beneficial role in reducing blood pressure and improving endothelial function, making it a target of interest in hypertension and heart failure research. It has shown protective effects in the kidneys by reducing proteinuria and glomerular damage, suggesting potential use in diabetic nephropathy and other renal diseases. In the context of metabolic disorders, Angiotensin 1-7 improves insulin sensitivity and glucose uptake, indicating a possible role in managing type 2 diabetes. Preclinical studies also highlight its ability to reduce lung inflammation and fibrosis, which has led to investigations into its use in respiratory conditions such as pulmonary hypertension and acute lung injury. Additionally, due to its anti-fibrotic properties, it is being studied in liver and cardiac fibrosis. Overall, Angiotensin 1-7 is considered a protective component of the renin-angiotensin system, with therapeutic potential in cardiovascular, renal, metabolic, and inflammatory diseases.